WIDE MOAT STOCKS COMPARISON

Checking

 

Stock Comparison

AstraZeneca PLC vs CSL Limited

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AstraZeneca PLC

AZN · London Stock Exchange

Market cap (USD)$251.7B
Gross margin (TTM)79.3%
Operating margin (TTM)22.7%
Net margin (TTM)17%
SectorHealthcare
IndustryPharmaceuticals
CountryGB
Data as of2026-08-23
69/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.

View AZN analysis

CSL Limited

CSL · ASX

Market cap (USD)$66.6B
Gross margin (TTM)51.1%
Operating margin (TTM)-23.3%
Net margin (TTM)-16.3%
SectorHealthcare
IndustryPharmaceuticals
CountryAU
Data as of2026-08-23
79/100
Moat score

Partial score covering 85% of segment weight.

Full stock profile

Dive deeper into CSL Limited's moat claims, evidence, and risks.

View CSL analysis

Comparison highlights

  • Segment focus: AstraZeneca PLC has 6 segments (46% in Oncology); CSL Limited has 3 segments (72.1% in CSL Behring).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: AstraZeneca PLC has 1 moat types across 1 domains; CSL Limited has 3 across 2.

Primary market context

AstraZeneca PLC

Oncology

Market

Innovator oncology therapeutics (branded prescription medicines)

Geography

Global

Customer

Hospitals, oncology clinics, payers

Role

Innovator biopharmaceutical company

Revenue share

46%

CSL Limited

CSL Behring

Market

Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases

Geography

Global

Customer

Hospitals, specialty pharmacies, physicians; payers and national health systems

Role

Vertically integrated biopharma (plasma collection -> fractionation/manufacturing -> commercial distribution)

Revenue share

72.1%

Side-by-side metrics

AstraZeneca PLC
CSL Limited
Ticker / Exchange
AZN - London Stock Exchange
CSL - ASX
Market cap (USD)
$251.7B
$66.6B
Gross margin (TTM)
79.3%
51.1%
Operating margin (TTM)
22.7%
-23.3%
Net margin (TTM)
17%
-16.3%
Sector
Healthcare
Healthcare
Industry
Pharmaceuticals
Pharmaceuticals
HQ country
GB
AU
Primary segment
Oncology
CSL Behring
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
69 / 100
79 / 100 (partial, 85% coverage)
Moat domains
Legal
Supply, Legal
Last update
2026-09-05
2026-09-05

Moat coverage

Shared moat types

No overlap yet.

AstraZeneca PLC strengths

IP Choke Point

CSL Limited strengths

Supply Chain ControlPhysical Network DensityGovernment Contracting Relationships

Segment mix

AstraZeneca PLC segments

Full profile >

Oncology

Oligopoly

46%

Cardiovascular, Renal and Metabolism (CVRM)

Competitive

19.9%

Respiratory & Immunology (R&I)

Oligopoly

15.5%

Infectious Disease

Oligopoly

1%

Rare Disease

Oligopoly

16%

Other Medicines

Competitive

1.6%

CSL Limited segments

Full profile >

CSL Behring

Oligopoly

72.1%

CSL Seqirus

Oligopoly

12.9%

CSL Vifor

Oligopoly

15.1%

Act on this comparison

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.